Transaction DateRecipientSharesTypePriceValue
13th December 2019Cary Sucoff50,000Open or private purchase$0.39$19,500.00
13th December 2019Michael Messinger5,000Open or private purchase$0.37$1,850.00
13th December 2019David N. Low300,000Open or private purchase$0.43$129,000.00
20th June 2019Cary Sucoff25,000Grant/award etc.$0.15$3,750.00
Contra Fect Corporation
Contra Fect Corporation logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

ContraFect Corp. is a clinical stage biotechnology company. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections.

Ticker: CFRX
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1478069
Employees: 20
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags